The MDS Foundation proudly partners with the following organizations
The MDS Foundation proudly partners with the following organizations
Phone within the US
1-(800)-637-0839Outside the US only
1-(609)-298-1035Address
The MDS Foundation
228 Park Ave S
PMB 118983
New York
NY 10003-1502
The MDS Foundation is a global nonprofit 501(c)(3) advocacy organization (EIN 22-3283911), supporting patients, families, and healthcare providers in the fields of MDS and related diseases for over 30 years.
© 2024 MDS Foundation. All rights reserved.
Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.
05
Dec
2025
Orlando, Florida
In recent years, significant progress has been made in understanding the biology, genetics, and pathogenesis of myelodysplastic syndromes (MDS). These advances have led to meaningful developments in how the disease is diagnosed, risk-stratified, and managed—insights that will be reflected in the upcoming revision of the International Treatment Guidelines, set to be presented and published by a leading global consortium of MDS experts.
Among the evolving topics in the field is the role of morphology in modern medicine—a question that has become increasingly relevant in 2025. This issue will be explored in depth during the program, along with an important discussion on the implications of germline mutations in MDS patients and how this growing body of knowledge necessitates a reassessment of current clinical approaches.
The continued need for more effective therapies has also inspired the inclusion of a dedicated session on drug development, with a specific focus on the MDS pipeline.
Aligned with our patient-centeredness, the program will also feature a patient-centered discussion to bridge the gap between scientific advancements and the lived experience of those navigating MDS in real-world settings.
Friday, December 5, 2025
Orange County Convention Center, West Concourse, Tangerine Ballroom; West E/F Lobby, Level 2, Orlando, Florida, United States
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other healthcare professionals interested in the treatment and management of patients with Myelodysplastic Syndromes and related neoplasms.
Participants will learn about novel information obtained over the last decade and will hear about potential applications in the field of MDS:
Learn about the latest international MDS guidelines and how they unify global standards for diagnosis and treatment, helping physicians deliver consistent, evidence-based care worldwide.
Explore when morphology remains essential in MDS diagnosis and how modern molecular and digital tools are reshaping laboratory practice and disease classification.
Review new insights on germline predisposition in MDS and discuss when proactive management or conservative monitoring offers the best outcomes for patients and families.
Gain a clear view of the MDS drug development process, from discovery to real-world application, and learn how clinical trials shape future treatment innovation.
Connect scientific evidence with real-life experiences as patients, clinicians, and researchers share insights on improving care, communication, and quality of life in MDS.
Moshe
Mittelman
MD
Valeria
Santini
MD
Rafael
Bejar
MD, PhD
Rena
Buckstein
MD, FRCPC
Carmelo
Gurnari
Robert
Hasserjian
Stephen D.
Nimer
MD
David P.
Steensma
MD, FACP
Peggy Ann
Torney
Arjan
van de Loosdrecht
MD, PhD
07:00 - 07:10 am
07:10 - 07:15 am
Valeria Santini, Florence, Italy
07:15 - 07:35 am
Rena Buckstein, Toronto, Canada
07:35 - 08:00 am
08:00 - 08:40 am
Moderator:
Expert Panel:
08:40 - 09:05 am
09:05 - 09:55 am
09:55 - 10:00 am
Valeria Santini, Florence, Italy
Follow the full Friday Satellite Symposium. Click below to access the livestream.
There is no fee to participate in this activity. Statements of credit will be awarded based on the participant's attendance. A statement of credit will be available upon completion of an online evaluation/claim credit form available at:
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and MDS. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 3 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum
of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Nurses
Credit being awarded: 3 ANCC contact hours
Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education
activity for 3 contact hours.
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Commercial Support
This program is made possible by the generous support of the following companies:
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.
